We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Methods Compared for Detection of Fecal Giardiasis

By LabMedica International staff writers
Posted on 27 Mar 2016
Microscopy for intestinal protozoa after formol-ether (FE) or formol-ethylacetate (FEA) concentration is standard procedure for investigating patients with diarrhea where a protozoan etiology is suspected. More...


In recent times, polymerase chain reaction (PCR) or fluorescence-labeled parasite-specific antibodies have been introduced for infections with intestinal protozoan parasites like Giardia duodenalis (syn. G. intestinalis and G. lamblia), Cryptosporidium but their place in everyday routine diagnostics has not yet been established.

Scientists at Aarhus University Hospital (Denmark) compared FEA and salt–sugar flotation (SSF) concentration followed by microscopy of iodine-stained concentrate and immunofluorescence assay (IFA) and real-time polymerase chain reaction (qPCR) for detection of Giardia duodenalis in human feces. Consecutive 455 fecal samples received between August 2012 and April 2013 at the hospital were included. FEA was performed within 48 hours after receipt of the samples. The samples were kept at + 4 °C for up to 90 days prior to qPCR analysis.

Immunofluorescence assays were performed on diluted feces after proper mixing, and a direct smear was made on Teflon coated slides containing three wells of 10 mm (Menzel Gläser, Braunschweig, Germany). The smears were left to air dry at room temperature overnight stained with FITC-labeled anti-Giardia antibodies (Cellabs; Brookvale Australia). Real-time polymerase chain reactions (qPCR) were performed where the crossing point-PCR-cycle (Cp) is the value given by the LightCycler 480 (Roche Diagnostics; Mannheim, Germany) and is similar to cycle threshold (Ct). It is the cycle at which fluorescence achieves a defined threshold.

The median number of Giardia cysts found by FEA in 19 Giardia-positive samples was 50 cysts per gram (CPG), by SSF 350 CPG, by IFA 76,700 CPG, and by qPCR 316,000 CPG. The team next tested 455 consecutive samples for presence of Giardia cysts. Using IFA as reference, qPCR had a sensitivity of 91%, specificity of 95.1%, a false-positive rate of 50%, a false-negative rate of 0.48%, a positive predictive value of 50%, and a negative predictive value of 99.5%.

The authors concluded that qPCR and IFA were significantly more sensitive than microscopy of iodine-stained concentrates using either FEA or SSF. They suggest, when using qPCR, that positive samples are verified by IFA to prevent false-positive results. The study was published in the March 2016 issue of the journal Diagnostic Microbiology and Infectious Disease.

Related Links:
Aarhus University Hospital
Menzel Gläser 
Cellabs 



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.